FLT3 mutation is a highly relevant target given its specificity and role in the biology of AML. There are a number of small-molecule receptor tyrosine kinase inhibitors that target FLT3 ...

Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...

This type of AML can be treated with established drugs called FLT3 inhibitors, but the cancer often develops resistance to this treatment over time. Because the RSK1 inhibitor blocks a different ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...

The drugs targeting FLT3 rewire the cell, resulting in the upregulation of other signaling pathway associated genes, which then restored AP-1 and RUNX1 binding. Drugging RAS, which is a key ...

This is an electron microscopy visualization of AML cells treated with Flt3 inhibitor showing mitophagy. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases ...

a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa ...

The European Medicines Agency (EMA) has given the nod to an accelerated assessment for quizartinib – a second-generation FLT3 inhibitor – as a second-line therapy for adult AML patients with ...

There are now several classes of FLT3 inhibitors in development with varying degrees of potency and selectivity for the target, including several in late-phase clinical trials in combination with ...